Clinical trials: Rectal Cancer, Radiotherapy
Locally Advanced Rectal Carcinoma
Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer
The goal of this clinical trial is to test the efficacy and safety in patients with locally advanced middle and lower rectal cancer.
- Trial name
- NeoCaCRT (NCT05792735)
- Testing
- Cadonilimab Injection, Short-course radiotherapy, Consolidation chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Shenzhen People's Hospital
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neoplasms, Second Primary
Secondary Cancer Risk After Radiation Therapy for Rectal Cancer
Retrospective study comparing dose distribution of 3D conformal radiotherapy (3DCRT) and volumetric-modulated arc therapy (VMAT) to estimate secondary cancer risk for patients having had radiation therapy for rectal cancer.
- Trial name
- NCT02572362
- Testing
- No intervention in this retrospective study
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- Kantonsspital Graubünden
Rectal Neoplasms
Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery
This pilot clinical trial studies gene expression analysis and fludeoxyglucose F 18 (FDG) positron emission tomography (PET)/magnetic resonance imaging (MRI) in evaluating treatment response in patients with rectal cancer that…
- Trial name
- NCT02112162
- Testing
- fludeoxyglucose F 18, positron emission tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Rectal Neoplasms
Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET
The purpose of this study is to investigate if PET/CT and MRI scans performed early in treatment and six weeks after treatment can predict the response of rectal cancer following chemotherapy and radiotherapy.
- Trial name
- PRISM (NCT02233374)
- Testing
- Early MRI and PET/CT - 2 weeks after commencing chemo/RT, Late MRI and PET/CT 6 weeks post chemo/RT
- Where
- Australia
- Volunteers
- 27 people
- Sponsor
- Royal North Shore Hospital
Cancer, Endometrial Cancer
Adaptive Radiotherapy for Safe Hypofractionation
This phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) evaluates whether daily online adaptive radiotherapy (ART) enables the safe delivery of hypofractionated, iso-biologically equivalent (EQD2)…
- Conditions
- Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer
- Trial name
- ART-Hypo (NCT07516210)
- Testing
- Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy
- Where
- Canada
- Volunteers
- 264 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostatic Adenocarcinoma
Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid
The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5…
- Trial name
- RPAH2 (NCT02361515)
- Testing
- Moderate hypofractionated radiotherapy, Stereotactic radiotherapy
- Where
- 7 sites in France
- Volunteers
- 96 people
- Sponsor
- Hospices Civils de Lyon
Rectal Cancer, Rectal Adenocarcinoma
Chemo-radiotherapy as Main Treatment Strategy for Rectal Cancer. Can we Provide a More Precise and Effective Treatment
The purpose of this project is to obtain important information about the tumour and surrounding organs during preoperative chemo-radiotherapy for patients with adenocarcinoma of the rectum.
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Locally Advanced Malignant Neoplasm
- Trial name
- AMPERE (NCT03619668)
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- Aalborg University Hospital
Rectal Cancer
A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.
Surgery is the most indicated curative treatment for rectal cancer when disease is diagnosed early, however local recurrence risk increases when the disease is diagnosed at advanced stage.T1-2 tumors have a recurrence rate lower…
- Trial name
- NCT01941979
- Testing
- 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
- Where
- Brazil
- Volunteers
- 309 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colonic Neoplasms, Neoplasm Metastasis
A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely
The proposed study will evaluate if "curative intent" SBRT can provide high response rates and clinically meaningful cancer control with acceptable toxicity specifically in patient with metastatic colorectal cancer (mCRC) who do…
- Trial name
- NCT03175146
- Testing
- Stereotactic Body Radiation Therapy
- Volunteers
- 30 people
- Sponsor
- AHS Cancer Control Alberta
Sarcoma, Rectal Carcinoma
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
THEODORA is a prospective pilot clinical trial aiming at first to evaluate and validate the predictive value of the A \& MS bioassays on tumor control by radiotherapy.
- Conditions
- Sarcoma, Rectal Carcinoma, Esophagus Cancer
- Trial name
- THEODORA (NCT02797405)
- Testing
- Standard treatment
- Where
- 7 sites in France
- Volunteers
- 97 people
- Sponsor
- Centre Leon Berard
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients
Total neoadjuvant treatment (TNT) including radiotherapy and induction or consolidation systemic chemotherapy has become the standard treatment for patients with stage II and III rectal adenocarcinoma.
- Trial name
- PREDIR-NEOREC (NCT06762405)
- Testing
- radiotherapy, Dostarlimab, Biological study on circulating tumor DNA (optional for the patient)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Cancer, GPA33
Phase IIT Trial of SNA009
This clinical trial is a single-center, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and radiation dosimetry of 68Ga-NODAGA-SNA009 in patients with colorectal cancer.
- Trial name
- NCT07597759
- Testing
- 68Ga-NODAGA-SNA009
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
Cancer of Rectum, Cancer of the Rectum
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
The purpose of this research study is to look at how tumors responds to a short course of radiation (5 days) followed by 8 cycles of chemotherapy.
- Conditions
- Cancer of Rectum, Cancer of the Rectum, Neoplasm, Rectum, Rectal Cancer
- Trial name
- NORMAL-R (NCT02641691)
- Testing
- Radiation, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Unresectable Locally Recurrent Rectal Cancer
Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer
Research Objectives and Principles: Through a prospective study, explore the effectiveness and safety of stereotactic body radiation therapy (SBRT) in the treatment of unresectable locally recurrent rectal cancer (ULRRC)…
- Trial name
- NCT07297004
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer
Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)
The goal of this clinical trial is to learn if neoadjuvant short-course radiation (SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 works to treat patients with locally advanced rectal cancer (LARC).
- Trial name
- NeoCaCRT-III (NCT06832917)
- Testing
- AK104 plus, Chemo only
- Volunteers
- 238 people
- Sponsor
- Wan He
Enteritis
A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer
The purpose of this study is to evaluate the safety and preliminary efficacy of four doses of SGX201 in subjects with rectal cancer treated with concurrent radiation and chemotherapy.
- Trial name
- NCT01073384
- Testing
- SGX201 (delayed release beclomethasone 17,21-dipropionate)
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Soligenix
Anal Cancer, Recurrent Anal Cancer
Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)
This protocol aims to determine toxicity and efficacy of re-irradiation for patients with recurrences from anal cancers with dose-escalated pencil beam proton therapy either pre-operative for marginally resectable recurrences or…
- Trial name
- ReRad III (NCT05055635)
- Testing
- Pencil beam proton therapy
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- University of Aarhus
Breast Cancer, Prostate Cancer
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
The goal of this clinical trial is to evaluate single-fraction metastases-directed SBRT in the broader radiation oncology community and to compare its safety and efficacy profile with the current Standard of Care (SoC) of…
- Conditions
- Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer
- Trial name
- SPRINT (NCT06462963)
- Testing
- single-fraction SBRT, multiple-fraction SBRT
- Where
- 15 sites in Belgium, Italy and 2 more
- Volunteers
- 302 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC